APPLICATION OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR FOLLOWING ALLOGENEIC BONE MARROWTRANSPLATATION
Lu Daopei;Guo Nailan;Zheng Huan;et al(Instdute of Hematolgy,People's Hospital,BeijingMedical University,Beijing,100044)
he effectiveness of recombinant human granulocyte-macrophage coIony stimu lating factor(rhGM-CSF,Leucomax by Schering-plough)was evaluated in 25 pa-tients with leukemia after al logeneic hi2ne marrow trans-plantation (allo-BMT).rhGM-CSF was administered ata dose of 5μg·kg￣(-1)/d by continuous intravenous infu-sion over 4 hours,starting from day 6 post BMT for 20consecutive days or ending with the WBC≥2×10￣9/L orneutrophil≥1×10￣9 /L for 3 consecutive days, The meandurations for leukocyte to reach greater than 1 × 10￣9/Land 2.0×10￣9/L were 18. 3 and 23.0 days respectively inthe rhGM-CSF-treated group v.s. 23. 8 and 3 3.3 daysin the paired chronological control group(P 0.00 1 and0.005 respectively).The neutrophil recovery(0.5×10￣9 /L and 1.0× 10￣9/L)was also significantly fasterfor the patients given rhGM-CSF(mean durations 17.7and 20.9 days)than that of the control(mean durations22.8 and 29.8 days)(P0.001).However, no differ-ences were noted in durations for platelets to reachgreater than 2 0 × 10￣9/L or in requirements of plateletconcentrates transfusion between rhGM-CSF-treated pa-tients and controls. No obvious adverse events were not-ed in all patients. It is concluded that rh GMCSF signifi-cantly increases neutrophils and total leukocyte counts inthe early stage after bone marrow transplantation.